Publications

BibTex format

@article{Roe:2019:10.1161/CIRCULATIONAHA.119.042551,
author = {Roe, MT and Li, QH and Bhatt, DL and Bittner, VA and Diaz, R and Goodman, SG and Harrington, RA and Jukema, JW and Lopez-Jaramillo, P and Lopes, RD and Louie, MJ and Moriarty, PM and Szarek, M and Vogel, R and White, HD and Zeiher, AM and Baccara-Dinet, MT and Steg, PG and Schwartz, GG and Steg, PG and Bhatt, DL and Bittner, VA and Diaz, R and Goodman, SG and Harrington, RA and Jukema, JW and Szarek, M and Zeiher, AM and Tricoci, P and Roe, MT and Mahaffey, KW and Edelberg, JM and Hanotin, C and Lecorps, G and Moryusef, A and Pordy, R and Sasiela, WJ and Tamby, J-F and Aylward, PE and Drexel, H and Sinnaeve, P and Dilic, M and Gotcheva, NN and Goodman, SG and Prieto, J-C and Yong, H and Lopez-Jaramillo, P and Pecin, I and Reiner, Z and Ostadal, P and Poulsen, SH and Viigimaa, M and Nieminen, MS and Danchin, N and Chumburidze, V and Marx, N and Liberopoulos, E and Valdovinos, PCM and Tse, H-F and Kiss, RG and Xavier, D and Zahger, D and Valgimigli, M and Kimura, T and Kim, HS and Kim, S},
doi = {10.1161/CIRCULATIONAHA.119.042551},
journal = {Circulation},
pages = {1578--1589},
title = {Risk categorization using New American College of Cardiology/American Heart Association guidelines for cholesterol management and its relation to alirocumab treatment following acute coronary syndromes},
url = {http://dx.doi.org/10.1161/CIRCULATIONAHA.119.042551},
volume = {140},
year = {2019}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background:The 2018 US cholesterol management guidelines recommend additional lipid-lowering therapies for secondary prevention in patients with low-density lipoprotein cholesterol ≥70 mg/dL or non−high-density lipoprotein cholesterol ≥100 mg/dL despite maximum tolerated statin therapy. Such patients are considered at very high risk (VHR) based on a history of >1 major atherosclerotic cardiovascular disease (ASCVD) event or a single ASCVD event and multiple high-risk conditions. We investigated the association of US guideline-defined risk categories with the occurrence of ischemic events after acute coronary syndrome and reduction of those events by alirocumab, a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor.Methods:In the ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab), patients with recent acute coronary syndrome and residual dyslipidemia despite optimal statin therapy were randomly assigned to alirocumab or placebo. The primary trial outcome (major adverse cardiovascular events, ie, coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, or hospitalization for unstable angina) was examined according to American College of Cardiology/American Heart Association risk category.Results:Of 18 924 participants followed for a median of 2.8 years, 11 935 (63.1%) were classified as VHR: 4450 (37.3%) had multiple prior ASCVD events and 7485 (62.7%) had 1 major ASCVD event and multiple high-risk conditions. Major adverse cardiovascular events occurred in 14.4% of placebo-treated patients at VHR versus 5.6% of those not at VHR. In the VHR category, major adverse cardiovascular events occurred in 20.4% with multiple prior ASCVD events versus 10.7% with 1 ASCVD event and multiple high-risk conditions. Alirocumab was associated with consistent relative risk reductions in both risk categories (hazard ratio=0.84 for VHR; hazard rati
AU  - Roe,MT
AU  - Li,QH
AU  - Bhatt,DL
AU  - Bittner,VA
AU  - Diaz,R
AU  - Goodman,SG
AU  - Harrington,RA
AU  - Jukema,JW
AU  - Lopez-Jaramillo,P
AU  - Lopes,RD
AU  - Louie,MJ
AU  - Moriarty,PM
AU  - Szarek,M
AU  - Vogel,R
AU  - White,HD
AU  - Zeiher,AM
AU  - Baccara-Dinet,MT
AU  - Steg,PG
AU  - Schwartz,GG
AU  - Steg,PG
AU  - Bhatt,DL
AU  - Bittner,VA
AU  - Diaz,R
AU  - Goodman,SG
AU  - Harrington,RA
AU  - Jukema,JW
AU  - Szarek,M
AU  - Zeiher,AM
AU  - Tricoci,P
AU  - Roe,MT
AU  - Mahaffey,KW
AU  - Edelberg,JM
AU  - Hanotin,C
AU  - Lecorps,G
AU  - Moryusef,A
AU  - Pordy,R
AU  - Sasiela,WJ
AU  - Tamby,J-F
AU  - Aylward,PE
AU  - Drexel,H
AU  - Sinnaeve,P
AU  - Dilic,M
AU  - Gotcheva,NN
AU  - Goodman,SG
AU  - Prieto,J-C
AU  - Yong,H
AU  - Lopez-Jaramillo,P
AU  - Pecin,I
AU  - Reiner,Z
AU  - Ostadal,P
AU  - Poulsen,SH
AU  - Viigimaa,M
AU  - Nieminen,MS
AU  - Danchin,N
AU  - Chumburidze,V
AU  - Marx,N
AU  - Liberopoulos,E
AU  - Valdovinos,PCM
AU  - Tse,H-F
AU  - Kiss,RG
AU  - Xavier,D
AU  - Zahger,D
AU  - Valgimigli,M
AU  - Kimura,T
AU  - Kim,HS
AU  - Kim,S-H
AU  - Kedev,S
AU  - Erglis,A
AU  - Laucevicius,A
AU  - Yusoff,K
AU  - Lopez,R
AU  - Ramos,Lopez GA
AU  - Alings,M
AU  - Halvorsen,S
AU  - Correa,Flores RM
AU  - Sy,RG
AU  - Budaj,A
AU  - Morais,J
AU  - Dorobantu,M
AU  - Karpov,Y
AU  - Ristic,AD
AU  - Chua,T
AU  - Murin,J
AU  - Fras,Z
AU  - Dalby,AJ
AU  - Tunon,J
AU  - de,Silva HA
AU  - Hagstrom,E
AU  - Muller,C
AU  - Chiang,C-E
AU  - Sritara,P
AU  - Guneri,S
AU  - Parkhomenko,A
AU  - Ray,KK
AU  - Moriarty,PM
AU  - Roe,MT
AU  - Chaitman,B
AU  - Kelsey,SF
AU  - Olsson,AG
AU  - Rouleau,J-L
AU  - Simoons,ML
AU  - Alexander,K
AU  - Meloni,C
AU  - Rosenson,R
AU  - Sijbrands,EJG
AU  - Alexander,JH
AU  - Armaganijan,L
AU  - Bagai,A
AU  - Bahit,MC
AU  - Brennan,JM
AU  - Clifton,S
AU  - DeVore,AD
AU  - Deloatch,S
AU  - Dickey,S
AU  - Dombrowski,K
AU  - Ducrocq,G
AU  - Eapen,Z
AU  - Endsley,P
AU  - Eppinger,A
AU  - Harrison,RW
AU  - Hess,CN
AU  - Hlatky,MA
AU  - Jordan,JD
AU  - Knowles,JW
AU  - Kolls,BJ
AU  - Kong,DF
AU  - Leonardi,S
AU  - Lillis,L
AU  - Maron,DJ
AU  - Marcus,J
AU  - Mathews,R
AU  - Mehta,RH
AU  - Mentz,RJ
AU  - Moreira,HG
AU  - Patel,CB
AU  - Pereira,SB
AU  - Perkins,L
AU  - Povsic,TJ
AU  - Puymirat,E
AU  - Jones,WS
AU  - Shah,BR
AU  - Sherwood,MW
AU  - Stringfellow,K
AU  - Sujjavanich,D
AU  - Toma,M
AU  - Van,Diepen SFP
AU  - Wilson,MD
AU  - Yan,AT-K
AU  - Lopes,RD
AU  - Trotter,C
AU  - Schiavi,LB
AU  - Garrido,M
AU  - Alvarisqueta,AF
AU  - Sassone,SA
AU  - Bordonava,AP
AU  - Alves,De Lima AE
AU  - Schmidberg,JM
AU  - Duronto,EA
AU  - Caruso,OC
AU  - Novaretto,LP
AU  - Angel,Hominal M
AU  - Montana,OR
AU  - Caccavo,A
AU  - Gomez,Vilamajo OA
AU  - Lorenzatti,AJ
AU  - Cartasegna,LR
AU  - Paterlini,GA
AU  - Mackinnon,IJ
AU  - Caime,GD
AU  - Amuchastegui,M
AU  - Salomone,R
AU  - Codutti,OR
AU  - Jure,HO
AU  - Bono
DO  - 10.1161/CIRCULATIONAHA.119.042551
EP  - 1589
PY  - 2019///
SN  - 0009-7322
SP  - 1578
TI  - Risk categorization using New American College of Cardiology/American Heart Association guidelines for cholesterol management and its relation to alirocumab treatment following acute coronary syndromes
T2  - Circulation
UR  - http://dx.doi.org/10.1161/CIRCULATIONAHA.119.042551
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494805400011&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/78703
VL  - 140
ER  -

Download

Professor Kazuhiro Ito

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)